The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide

BACKGROUND: In patients with bone metastatic castration-resistant prostate cancer (bmCRPC) on systemic treatment, it is difficult to differentiate between continuous rise of prostate specific antigen (PSA) representing progression, and PSA-surge, which is followed by clinical response or stable dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Poteska, Renata, Rahbar, Kambiz, Semjonow, Axel, Schrader, Andres Jan, Boegemann, Martin, Schlack, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994227/
https://www.ncbi.nlm.nih.gov/pubmed/35395766
http://dx.doi.org/10.1186/s12885-022-09483-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994227/
https://www.ncbi.nlm.nih.gov/pubmed/35395766
http://dx.doi.org/10.1186/s12885-022-09483-7

Ejemplares similares